SciBase Study Validates Nevisense EIS as Superior Skin Barrier Assessment Tool
Event summary
- SciBase published a study in *Contact Dermatitis* comparing Nevisense EIS to TEWL and Corneometry for assessing skin barrier integrity.
- The study found Nevisense EIS detected subtle structural changes not captured by TEWL measurements.
- Researchers suggest EIS could serve as an early biomarker for skin barrier damage due to its dependence on cell cohesion and lipid composition.
- The study was published in April 2026, Volume 94, Issue 4 of *Contact Dermatitis*.
- SciBase is listed on the Nasdaq First North Growth Market since June 2, 2015.
The big picture
The validation of Nevisense EIS strengthens SciBase's position in the growing market for AI-powered diagnostic solutions in dermatology. The study's findings suggest a shift towards more sensitive and early detection methods for skin disorders, potentially impacting the development of new treatments and preventative measures. This could be particularly valuable in addressing the increasing prevalence of skin conditions linked to environmental factors and aging populations.
What we're watching
- Adoption Rate
- The pace at which dermatologists and researchers integrate Nevisense EIS into their workflows will determine the technology's commercial success, particularly given the established use of TEWL and Corneometry.
- Clinical Utility
- How the early biomarker potential of EIS translates into improved patient outcomes and reduced healthcare costs will be crucial for securing broader clinical adoption and reimbursement.
- Competitive Landscape
- Whether competitors develop alternative or improved skin barrier assessment technologies will impact SciBase's market share and pricing power in the long term.
Related topics